SMAD3 and diabetic kidney disease: Smad2 and Smad3 are activated in kidneys of patients with CKD and experimental animals of unilateral ureteral obstruction (UUO), 5/6 nephrectomy, hypertensive nephropathy and diabetic nephropathy [49–54].